Campbell Newman Asset Management Inc Ligand Pharmaceuticals Inc Transaction History

Campbell Newman Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 Apr 09, 2019	SELL	$105.93 - $142.47 $432,618 - $581,847	-4,084 Closed	0 $0
Q4 2018 Jan 18, 2019	BUY	$128.36 - $272.13 $202,167 - $428,604	1,575 Added 62.77%	4,084 $554,000
Q3 2018 Oct 15, 2018	SELL	$211.18 - $274.49 $276,012 - $358,758	-1,307 Reduced 34.25%	2,509 $689,000
Q2 2018 Jul 25, 2018	BUY	$150.77 - $207.98 $24,726 - $34,108	164 Added 4.49%	3,816 $791,000
Q1 2018 Apr 25, 2018	BUY	$138.63 - $182.62 $21,764 - $28,671	157 Added 4.49%	3,652 $603,000
Q4 2017 Jan 25, 2018	BUY	$128.36 - $147.04 $81,765 - $93,664	637 Added 22.29%	3,495 $479,000
Q3 2017 Oct 11, 2017	BUY	$120.91 - $137.94 $44,011 - $50,210	364 Added 14.6%	2,858 $389,000
Q2 2017 Aug 09, 2017	BUY	N/A	2,494	2,494 $303,000

277

18.5M

30.8K

5.2K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.82B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Campbell Newman Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Campbell Newman Asset Management Inc with notifications on news.